產(chǎn)品詳情
簡單介紹：
重組人白細胞介素-36β，153a.a.蛋白與其它公司提供的重組蛋白不同，rHuIL-36β, 153a.a.蛋白產(chǎn)品為采用CFS的無細胞麥胚蛋白合成系統(tǒng)表達出來的重組蛋白，可表達出對細胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時獨有的全自動蛋白純化技術則簡便高效，將蛋白純化過程中對蛋白的損傷降低到*小程度.重組人白細胞介素-36β，153a.a.蛋白（全長序列）產(chǎn)品可用于Western Blot驗證、抗體制備、蛋白檢測、ELISA等試驗中.
詳情介紹：
重組人白細胞介素-36β，153a.a.蛋白
| Synonyms | FIL1 eta, IL-1 eta, IL-1F8, IL-1H2 |
| Species | Human |
| Accession | Q9NZH7-2 |
| GeneID | 27177 |
| Source | Escherichia coli. |
| Molecular Weight | 重組人白細胞介素-36β，153a.a.蛋白Approximately 17.2 kDa, a single non-glycosylated polypeptide chain containing 153 amino acids. |
| Quantity | 2μg/10μg/1000μg |
| AA Sequence | REAAPKSYAI RDSRQMVWVL SGNSLIAAPL SRSIKPVTLH LIACRDTEFS DKEKGNMVYL GIKGKDLCLF CAEIQGKPTL QLKEKNIMDL YVEKKAQKPF LFFHNKEGST SVFQSVSYPG WFIATSTTSG QPIFLTKERG ITNNTNFYLD SVE |
| Purity | > 97 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | 重組人白細胞介素-36β，153a.a.蛋白Fully biologically active when compared to standard. The ED50 as determined by inducing IL-8 secretion in human preadipocytes is less than 10 ng/ml, corresponding to a specific activity of > 1.0 × 105 IU/mg. |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in 2 × PBS, pH 7.4. |
| Endotoxin | 重組人白細胞介素-36β，153a.a.蛋白Less than 1 EU/μg of rHuIL-36β, 153a.a. as determined by LAL method. |
| Reconstitution | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at - 20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重組人白細胞介素-36β，153a.a.蛋白 | |
| SDS-PAGE |
|
| Reference |
1. Nicklin MJ, Barton JL, Nguyen M, et al. 2002. Genomics. 79:718-25. 2. Dinarello C, Arend W, Sims J, et al. 2010. Nat Immunol. 11:973. 3. Magne D, Palmer G, Barton JL, et al. 2006. Arthritis Res Ther. 8:R80. 4. van Asseldonk EJ, Stienstra R, Koenen TB, et al. 2010. Obesity (Silver Spring). 18:2234-6. 5. Johnston A, Xing X, Guzman AM, et al. 2011. J Immunol. 186:2613-22. |
| Background | Interleukin-36 (IL-36) is a pro-inflammatory cytokine which plays an important role in the pathophysiology of several diseases. IL-36α, IL-36β, and IL-36γ (formerly IL-1F6, IL-1F8, and IL-1F9) are IL-1 family members that signal through the IL-1 receptor family members IL-1Rrp2 (IL-1RL2) and IL-1RAcP. IL-36 beta is reported to be expressed at higher levels in psoriatic plaques than in symptomless psoriatic skin or healthy control skin and it can stimulate production of interleukin-6 and interleukin-8 in synovial fibrobasts, articular chondrocytes and mature adipocytes. It has two isoforms. IL-36β isoform 2 contains one potential N-linked glycosylation site in its C-terminus, while IL-36β isoform 1 lacks potential N-linked glycosylation sites and four of the conserved β-strands. Human IL-36βisoform 2 shares 62 %, 67 %, 63 % and 59 % a.a. identity with the most similar isoform of mouse, canine, bovine and equine IL-36β, respectively. |
